Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc.'s Q·Score is 4.9/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: low return on equity (-198%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for EDIT is $5.72, based on ratings from 9 Wall Street analysts. This is 97.3% above the current price of $2.90. Price targets are forward-looking estimates and not guarantees of future performance.

Editas Medicine, Inc. (EDIT) scores in line with sector averages on valuation metrics. The consensus analyst price target of $5.72 is 97% above the current price.

Editas Medicine, Inc. is scheduled to report earnings in 12 days, on May 15, 2026.

Editas Medicine, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at -122.0%, reflecting a more cost-intensive business model.

Editas Medicine, Inc. is reporting revenue declining 19.2% year-over-year.

Editas Medicine, Inc. has a debt-to-equity ratio of 0.66×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 3.54×, indicating comfortable short-term liquidity.